Injection
Tirzepatide + B12
A weekly dual-action GLP-1/GIP injection for meaningful weight loss and appetite control, paired with vitamin B12 for energy.
Starting at $198/mo
Weight lossGLP-1 / GIP
Tirzepatide + Glycine
RxPrescription onlyInjected under the skin · Once a week · 2.5–15 mg · Weight loss · GLP-1 / GIP
Starting at $198/mo
A physician-guided tirzepatide plan designed to support appetite regulation, metabolic health, and long-term care beyond the scale, with glycine for tolerance.
Choose your plan
Real prices from our pharmacy. Longer plans cost less per month and are billed up front. Pause or cancel anytime.
- Supports the gut-brain signals that help regulate fullness
- Once-weekly dual GLP-1/GIP injection, dosed and adjusted by your physician
- Paired with glycine to support tolerance and steadier digestion
Every plan includes
- Personalized, physician-guided plan
- Monthly, 3-month and 6-month plans
- Same price at every dose, no dose upcharges
- Dispensed by a US-licensed compounding pharmacy
- Unlimited dose adjustments and messaging
- Ongoing support and check-ins
- Pause or cancel anytime
- Physician-guided care
- Ongoing, expert support
- 100% online
- Free, discreet shipping
What is Tirzepatide?
(tir-ZEP-a-tide, a dual GLP-1 / GIP receptor agonist)
Your body makes GLP-1 and GIP after you eat. They are the signals that tell the brain “we've had enough,” slow digestion and steady blood sugar. Tirzepatide mimics both hormones at once, which is why it produced the largest weight loss seen in clinical trials of this class.
- How it is taken
- Injected under the skin
- How often
- Once a week
- Dose range
- 2.5–15 mg
- Form
- Weight loss · GLP-1 / GIP
up to 21%
Average body weight reduction in the pivotal clinical trial of brand-name tirzepatide
In the pivotal SURMOUNT-1 trial, adults with obesity lost up to about 21% of body weight over 72 weeks with once-weekly brand-name tirzepatide plus lifestyle changes. Compounded tirzepatide is not the brand-name product and was not studied in that trial; individual results vary.
How it works,
week by week.
Day 1
A US-licensed physician reviews your health profile, goals and treatment history and sets your starting dose.
7 Days
Your first weekly injection. Appetite usually quiets within days; some nausea in the first weeks is common and fades as the dose settles.
30 Days
Fullness comes sooner and cravings soften. Your physician checks how you feel before any dose increase.
6 Months
Weight loss builds steadily with the plan, food and movement. Doses are adjusted at your check-ins.
1 Year and Beyond
Maintenance is part of the plan: your physician decides with you how to hold your results or taper.
What you may notice,
and when.
Weight loss
steady and sustained, with your physician adjusting the dose
Appetite regulation
the most common change members report in their first weeks
Metabolic health
steadier blood sugar after meals
Tolerance
glycine helps many members tolerate the first weeks better
Individual results vary. Benefits reflect what Zepym Health members commonly report to their physician at check-ins; they are not the results of a clinical trial.
Safety first:
what to know before you start.
Is tirzepatide right for you?
GLP-1 medications are prescribed based on your BMI, your health history and your goals. Find your BMI on the chart to see whether you're within the usual range for treatment, then let your physician decide.
| BMI | Is tirzepatide right for me? |
|---|---|
| 24.9 or less | No |
| 25.0 to 29.9 | Case-by-case (with a weight-related condition) |
| 30.0 or above | Likely |
This chart is not a medical diagnosis. Your physician approves or declines a prescription at their discretion after reviewing your unique health profile; approval is not guaranteed by these criteria.
Important safety information and common side effects
Tirzepatide can cause nausea, vomiting, diarrhea, constipation, stomach pain, reduced appetite, fatigue and injection-site reactions, most often in the first weeks and when the dose goes up. Stop and seek care for severe stomach pain (possible pancreatitis or gallbladder problems), signs of an allergic reaction, or vision changes if you have diabetes. GLP-1 medications carry a boxed warning about thyroid C-cell tumors seen in rodents: do not use if you or a family member has had medullary thyroid carcinoma or MEN 2. Not for use in pregnancy or breastfeeding, or with a history of pancreatitis. Tell your physician about diabetes medication, insulin and every medication you take.
The research behind
tirzepatide.
Tirzepatide acts on two gut hormone receptors, GLP-1 and GIP. Its evidence is large randomized trials in adults with obesity, all with the injected form.
About the added ingredient: Glycine is an amino acid added to some blends. No human trial has tested it with tirzepatide for weight.
- Weightabout 21%
SURMOUNT-1: 2,539 adults with obesity, or overweight with a weight-related condition, 72 weeks of weekly injections at 5, 10 or 15 mg. At 15 mg the mean loss was 20.9% (intention to treat), against 3.1% on placebo.
SURMOUNT-1, NEJM 2022 - Head to head20.2% vs 13.7%
SURMOUNT-5: 751 adults without diabetes, open label, 72 weeks. Maximum tolerated tirzepatide (10 or 15 mg) lost 20.2% on average; maximum tolerated semaglutide (1.7 or 2.4 mg) lost 13.7%.
SURMOUNT-5, NEJM 2025 - Large losses57% lost 20% or more
SURMOUNT-1 at 15 mg: 57% of people reached a loss of at least 20% of body weight, against 3% on placebo. The average hides a wide spread between people.
SURMOUNT-1, NEJM 2022
What the studies found
- Average weight loss of 20.9% at 72 weeks on the 15 mg dose, against 3.1% on placebo (SURMOUNT-1, NEJM 2022).
- Lost more weight than semaglutide in a head-to-head trial: -20.2% against -13.7% (SURMOUNT-5, NEJM 2025).
- Reduced apnea-hypopnea events per hour by 20 to 24 more than placebo over 52 weeks in adults with obesity and sleep apnea (SURMOUNT-OSA, NEJM 2024).
- Improved all prespecified cardiometabolic measures alongside weight loss (SURMOUNT-1, NEJM 2022).
- Kept most of the weight loss while continued: 89.5% kept at least 80% of their loss, against 16.6% on placebo (SURMOUNT-4, JAMA 2024).
Trial results are for the injected tirzepatide at the doses studied. They are averages, not predictions for one person. No trial has tested the sublingual (dissolve-under-the-tongue) form or the compounded blends.
What this does not say
- SURMOUNT-5 was open label and run by the manufacturer of tirzepatide, so the head-to-head result needs an independent check.
- The trials ran 52 to 72 weeks. Effects after stopping were not part of them, though SURMOUNT-4 shows regain after withdrawal.
- Between 4.3% and 7.1% of people on tirzepatide stopped for adverse events in SURMOUNT-1, against 2.6% on placebo.
The research
behind it.
GLP-1 and GIP are hormones the body makes after eating, telling the brain “we've had enough” while slowing digestion and steadying blood sugar. Tirzepatide amplifies both signals at once for a full week per dose.
In the pivotal SURMOUNT-1 trial, adults with obesity lost up to about 21% of body weight over 72 weeks with once-weekly brand-name tirzepatide plus lifestyle changes. In people with obesity but without diabetes, brand-name semaglutide also reduced major cardiovascular events in the SELECT trial. Compounded versions are prescribed by your physician when appropriate and are not the brand-name products.
GLP-1 beyond the scale:
what the research showsHeart, kidneys, liver, sleep and joints: the trials, with their numbers and their limits.Read the researchMicrodosing GLP-1:
what we know, and what we don’tLower doses are everywhere online. Here is what has actually been studied, and how our physicians use dose.Read the research
what the research showsHeart, kidneys, liver, sleep and joints: the trials, with their numbers and their limits.Read the researchMicrodosing GLP-1:
what we know, and what we don’tLower doses are everywhere online. Here is what has actually been studied, and how our physicians use dose.Read the research
Getting started
takes a few minutes.
- 1
Connect with a physician
Answer a few questions online and a US-licensed physician reviews your health, history and goals to make sure treatment is right for you. 100% online. No in-person visit required.
- 2
Get your discreet shipment
If approved, your treatment is compounded by a US-licensed, LegitScript-certified pharmacy, inspected for quality, and shipped discreetly to your door.
- 3
Receive continuous support
Start with one goal, then keep building over time. Unlimited physician messaging, easy refills and dose adjustments, all from the Zepym Health app.
Frequently asked questions
Contact supportHow do I use Tirzepatide + Glycine?
Injected under the skin, once a week. The starting prescription is 50 units (2.5 mg) each time. Your physician sets your own dose and it is printed on your label.
What strengths does Tirzepatide + Glycine come in?
The pharmacy carries 6: 10 mg (5 mg / 0.5 mg/mL), 20 mg (10 mg / 0.5 mg/mL), 30 mg (15 mg / 0.5 mg/mL), 40 mg (20 mg / 0.5 mg/mL), 50 mg (25 mg / 0.5 mg/mL), 60 mg (30 mg / 0.5 mg/mL). Your physician chooses which one you get.
What exactly is in it?
Tirzepatide, Glycine.
How much arrives in each shipment?
1 vial at the starting strength, shipped to your door from a licensed US pharmacy.
How does tirzepatide help with weight loss?
It mimics two gut hormones at once, GLP-1 and GIP, that tell your brain you're full, slow how fast your stomach empties and steady blood sugar after meals. You feel satisfied with less food, so eating less becomes sustainable rather than a fight.
What does the Glycine add?
Glycine is an amino acid that supports steadier digestion and sleep. Many members tolerate the first weeks better with it.
What are the side effects?
Nausea, constipation, diarrhea and fatigue are the most common, usually in the first weeks and after a dose increase, and they fade as your body adjusts. Serious but rare risks include pancreatitis and gallbladder problems; read the safety information above and tell your physician about any history of pancreatitis or thyroid cancer.
What happens when I reach my goal?
Your physician decides with you: some people hold a maintenance dose, others taper down gradually. Either way, the plan includes the habits, food and movement that keep the weight off.
Tirzepatide + Glycine educational content reviewed by our physician
Scott Nass, MD Doctor of Medicine, board-certified in Family Medicine
Charles R. Drew University and David Geffen School of Medicine at UCLA. Family Medicine residency at Ventura County Medical Center.
More options
in this area.
Injection
Semaglutide + B12
A weekly GLP-1 injection that quiets cravings and supports steady, sustainable weight loss, paired with vitamin B12 for energy.
Starting at $99/mo
Injection
Semaglutide + Glycine
A weekly GLP-1 injection that quiets cravings and supports steady, sustainable weight loss, paired with glycine for better tolerance.
Starting at $99/mo
Tablet
Metformin
Metformin commercial tablet for weight loss support and glucose metabolism. Take daily, 30-day supply.
30 tablets per month
Starting at $79/mo
References
- 1.Once-weekly tirzepatide produced mean weight loss of up to about 21% over 72 weeks in adults with obesity (SURMOUNT-1). New England Journal of Medicine, 2022 (Jastreboff AM et al.)
- 2.Semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity without diabetes (SELECT), evidence of the class's metabolic benefits. New England Journal of Medicine, 2023 (Lincoff AM et al.)
- 3.Mechanisms of GLP-1 and incretin hormones: appetite, gastric emptying and glucose regulation. Cell Metabolism, 2018 (Drucker DJ)
Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. Products are compounded by a licensed pharmacy. The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality. Compounded medications are not the FDA-approved brand-name products.